Mechanisms Leukotriene receptor antagonist, selective competitive inhibitor of LTD 4 and LTE 4 receptors. No specific adverse effects to date. As with any new drug, there is possibility of rare hypersensitivity or idiosyncratic reactions that cannot usually be detected in initial premarketing trials. Mechanisms 5-lipoxygenase inhibitor. Elevation of liver enzymes has been reported.
Limited case reports of reversible hepatitis and hyperbilirubinemia.
Zileuton is a microsomal CYP3A4 enzyme inhibitor that can inhibit the metabolism of terfenadine, warfarin, and theophylline. Doses of these drugs should be monitored accordingly. These drugs should not be used for treatment of acute exacerbations. Instead, these agents are usually used as an adjunct to inhaled corticosteroid therapy, particularly for control of nocturnal asthma symptoms. Prevention of exercise-induced bronchospasm.